SG11201808920RA - Genome editing of human neural stem cells using nucleases - Google Patents
Genome editing of human neural stem cells using nucleasesInfo
- Publication number
- SG11201808920RA SG11201808920RA SG11201808920RA SG11201808920RA SG11201808920RA SG 11201808920R A SG11201808920R A SG 11201808920RA SG 11201808920R A SG11201808920R A SG 11201808920RA SG 11201808920R A SG11201808920R A SG 11201808920RA SG 11201808920R A SG11201808920R A SG 11201808920RA
- Authority
- SG
- Singapore
- Prior art keywords
- stanford
- neural stem
- international
- stem cells
- human neural
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Developmental Biology & Embryology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662322652P | 2016-04-14 | 2016-04-14 | |
PCT/US2017/027504 WO2017180926A1 (en) | 2016-04-14 | 2017-04-13 | Genome editing of human neural stem cells using nucleases |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201808920RA true SG11201808920RA (en) | 2018-11-29 |
Family
ID=60037918
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201808920RA SG11201808920RA (en) | 2016-04-14 | 2017-04-13 | Genome editing of human neural stem cells using nucleases |
Country Status (8)
Country | Link |
---|---|
US (2) | US20170298348A1 (zh) |
EP (1) | EP3443085B1 (zh) |
JP (1) | JP7197363B2 (zh) |
CN (1) | CN109312308A (zh) |
AU (2) | AU2017250683A1 (zh) |
CA (1) | CA3020181A1 (zh) |
SG (1) | SG11201808920RA (zh) |
WO (1) | WO2017180926A1 (zh) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3613852A3 (en) | 2011-07-22 | 2020-04-22 | President and Fellows of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
US9228207B2 (en) | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
US20150166982A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting pi3k point mutations |
US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
IL294014B1 (en) | 2015-10-23 | 2024-03-01 | Harvard College | Nucleobase editors and their uses |
AU2017306676B2 (en) | 2016-08-03 | 2024-02-22 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
CA3033327A1 (en) | 2016-08-09 | 2018-02-15 | President And Fellows Of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
CN110214180A (zh) | 2016-10-14 | 2019-09-06 | 哈佛大学的校长及成员们 | 核碱基编辑器的aav递送 |
WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
JP2020510439A (ja) | 2017-03-10 | 2020-04-09 | プレジデント アンド フェローズ オブ ハーバード カレッジ | シトシンからグアニンへの塩基編集因子 |
KR20190130613A (ko) | 2017-03-23 | 2019-11-22 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제 |
WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
WO2019023680A1 (en) | 2017-07-28 | 2019-01-31 | President And Fellows Of Harvard College | METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE) |
US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
US11795443B2 (en) | 2017-10-16 | 2023-10-24 | The Broad Institute, Inc. | Uses of adenosine base editors |
EP3942040A1 (en) | 2019-03-19 | 2022-01-26 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
CN110075319A (zh) * | 2019-04-29 | 2019-08-02 | 白涛 | 一种抗遗传病生物导弹 |
EP4103177A4 (en) * | 2020-02-11 | 2024-03-27 | University of Virginia Patent Foundation | COMPOSITIONS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF EYE DISEASES |
MX2022014008A (es) | 2020-05-08 | 2023-02-09 | Broad Inst Inc | Métodos y composiciones para la edición simultánea de ambas cadenas de una secuencia de nucleótidos de doble cadena objetivo. |
KR20230019156A (ko) * | 2020-06-02 | 2023-02-07 | 카탈렌트 파마 솔루션즈, 엘엘씨 | 유전자 삽입을 위한 다수의 도크들이 있는 세포주 |
CN111925998A (zh) * | 2020-06-09 | 2020-11-13 | 广州再生医学与健康广东省实验室 | 模拟SARS-CoV-2感染的系统及其制备方法与应用 |
WO2022163770A1 (ja) * | 2021-01-28 | 2022-08-04 | 国立研究開発法人理化学研究所 | ゲノム編集ツールの評価方法 |
WO2023102712A1 (zh) * | 2021-12-07 | 2023-06-15 | 深圳市先康达生命科学有限公司 | 一种基因生物制剂及其制备方法和应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7217565B2 (en) | 1999-02-12 | 2007-05-15 | Stemcells California, Inc. | Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations |
US7037719B1 (en) | 1999-02-12 | 2006-05-02 | Stemcells California, Inc. | Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations |
US7105150B2 (en) | 1999-02-12 | 2006-09-12 | Stemcells California, Inc. | In vivo screening methods using enriched neural stem cells |
EP1540348A4 (en) | 2002-08-27 | 2006-10-11 | Stemcells California Inc | ENRICHED CELLS OF STEM CELLS AND PROGENITORS OF THE CENTRAL NERVOUS SYSTEM, AND METHODS OF IDENTIFYING, ISOLATING AND ENRICHING SUCH POPULATIONS |
WO2013158309A2 (en) * | 2012-04-18 | 2013-10-24 | The Board Of Trustees Of The Leland Stanford Junior University | Non-disruptive gene targeting |
PT2800811T (pt) | 2012-05-25 | 2017-08-17 | Univ California | Métodos e composições para modificação de adn alvo dirigida por arn e para modulação dirigida por arn de transcrição |
ES2769310T3 (es) * | 2012-12-06 | 2020-06-25 | Sigma Aldrich Co Llc | Modificación y regulación del genoma basada en CRISPR |
EP4279588A3 (en) | 2012-12-12 | 2024-01-17 | The Broad Institute, Inc. | Engineering of systems, methods and optimized guide compositions for sequence manipulation |
CA2926078C (en) | 2013-10-17 | 2021-11-16 | Sangamo Biosciences, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells |
CA2930590C (en) * | 2013-11-15 | 2021-02-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Engineering neural stem cells using homologous recombination |
WO2015188065A1 (en) * | 2014-06-05 | 2015-12-10 | Sangamo Biosciences, Inc. | Methods and compositions for nuclease design |
-
2017
- 2017-04-13 SG SG11201808920RA patent/SG11201808920RA/en unknown
- 2017-04-13 WO PCT/US2017/027504 patent/WO2017180926A1/en active Application Filing
- 2017-04-13 EP EP17783170.8A patent/EP3443085B1/en active Active
- 2017-04-13 AU AU2017250683A patent/AU2017250683A1/en not_active Abandoned
- 2017-04-13 CA CA3020181A patent/CA3020181A1/en active Pending
- 2017-04-13 US US15/487,309 patent/US20170298348A1/en not_active Abandoned
- 2017-04-13 CN CN201780036763.3A patent/CN109312308A/zh active Pending
- 2017-04-13 JP JP2018554450A patent/JP7197363B2/ja active Active
-
2023
- 2023-01-03 US US18/092,911 patent/US20230250423A1/en active Pending
- 2023-07-24 AU AU2023208065A patent/AU2023208065A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3020181A1 (en) | 2017-10-19 |
EP3443085B1 (en) | 2022-09-14 |
JP7197363B2 (ja) | 2022-12-27 |
US20230250423A1 (en) | 2023-08-10 |
US20170298348A1 (en) | 2017-10-19 |
AU2023208065A1 (en) | 2023-08-17 |
WO2017180926A1 (en) | 2017-10-19 |
EP3443085A4 (en) | 2019-09-25 |
EP3443085A1 (en) | 2019-02-20 |
AU2017250683A1 (en) | 2018-11-01 |
CN109312308A (zh) | 2019-02-05 |
JP2019511240A (ja) | 2019-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201808920RA (en) | Genome editing of human neural stem cells using nucleases | |
SG11201811292RA (en) | Compositions and methods for the depletion of cells | |
SG11201807187XA (en) | Binding members to pd-l1 | |
SG11201900138TA (en) | Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof | |
SG11201811719RA (en) | Conjugates for targeted cell surface editing | |
SG11201901996UA (en) | Formulations of ( r)-2-amino-3-phenylpropyl carbamate | |
SG11201901757YA (en) | Pd-1 homing endonuclease variants, compositions, and methods of use | |
SG11201909949XA (en) | Targeted immunotolerance | |
SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201809627QA (en) | Anti pd-1 and anti-lag3 antibodies for cancer treatment | |
SG11201809710RA (en) | Genetically engineered cells and methods of making the same | |
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201804375WA (en) | Compositions and methods for internalizing enzymes | |
SG11201807252QA (en) | Anti-lag-3 antibodies | |
SG11201909203WA (en) | Tissue selective transgene expression | |
SG11201808909WA (en) | Ex vivo bite-activated t cells | |
SG11201408405WA (en) | Engineered three-dimensional connective tissue constructs and methods of making the same | |
SG11201805680SA (en) | Methods and compositions for the treatment of neurologic disease | |
SG11201811251RA (en) | Multi-chamber deposition equipment for solid free form fabrication | |
SG11201809751XA (en) | Egfr inhibitor compounds | |
SG11201807593TA (en) | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers | |
SG11201807041PA (en) | Improved preparations of adult liver progenitor cells | |
SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
SG11201806400XA (en) | Replicative transposon system |